CUE (Cue Biopharma) Issuance of Stock : $19.96 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cue Biopharma Issuance of Stock?

Cue Biopharma's Issuance of Stock for the three months ended in Sep. 2024 was $10.82 Mil.

Cue Biopharma's Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2024 was $19.96 Mil.

Cue Biopharma Issuance of Stock Historical Data

The historical data trend for Cue Biopharma's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cue Biopharma Issuance of Stock Chart

Cue Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Issuance of Stock

Get a 7-Day Free Trial

49.00

56.68

17.39

39.30

13.39

Cue Biopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Issuance of Stock	Get a 7-Day Free Trial															5.59	5.78	3.35	-	10.82

Cue Biopharma Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.96 Mil.

Cue Biopharma Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Cue Biopharma's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Cue Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cue Biopharma Inc (NAS:CUE) » Definitions » Issuance of Stock

Comparable Companies

Traded in Other Exchanges

1UC:Germany

Address

40 Guest Street, Boston, MA, USA, 02135

Website

https://www.cuebiopharma.com

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Executives

Anish Suri	officer: President and CSO	40 GUEST STREET, BOSTON MA 02135
Daniel R Passeri	director, officer: CEO	40 GUEST STREET, BOSTON MA 02135
Pamela Garzone	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Patrick Verheyen	director	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Peter A Kiener	director	40 GUEST STREET, BOSTON MA 02135
Matteo Levisetti	officer: Chief Medical Officer	C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON MA 02135
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Patricia Nasshorn	officer: Chief Business Officer	C/O WOMEN FIRST HEALTHCARE INC, 12220 EL CAMINO REAL, SAN DIEGO CA 92130
Kerri-ann Millar	officer: CFO	40 GUEST STREET, BOSTON MA 02135
Kenneth Pienta	officer: Chief Medical Officer	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Sandercock Colin	officer: SVP, General Counsel and Sec	40 GUEST STREET, BOSTON MA 02135
Tamar D Howson	director
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Frederick W Driscoll	director